tirzepatide and vision changes Macular Degeneration: Current Evidence and Monitoring weeksout:1-0 Tamaño:30 mg GLP-1 Agonists—commonly used for

tirzepatide and vision changes Macular Degeneration: Current Evidence and Monitoring weeksout:1-0 Tamaño:30 mg GLP-1 Agonists—commonly used for

GLP-1 Agonists—commonly used for weight loss and diabetes—are now being linked to serious eye health concerns, including an increased risk of a condition called NAION, which can cause irreversible blindness. With GLP-1

Supplementary Information Acknowledgements Eli Lilly and Company would like to thank the clinical trial participants and their caregivers, without whom this work would not be possible

weeksout:1-0

Tamaño:30 mg

Concerns have arisen regarding compounded versions of GLP-1 drugs, with the FDA receiving over 700 adverse event reports due to dosing errors or unapproved formulations